洞察市场格局
解锁药品研发情报

客服电话

400-9696-311
医药数据查询

【Breaking News】前FDA资深专家王亚宁博士离开朗来科技,创办瑞宁康生物 (English Version)

2024/06/29
act 瑞宁康生物 王亚宁

DrugTimes has learned and confirmed that Dr. Yaning Wang, a senior industry expert who has worked for the US Food and Drug Administration (FDA) for 18 years and rose to the position of Director of the Quantitative Pharmacology Review Department in the Clinical Pharmacology Review Office, has left Createrna Science and Technology and founded a new company.。 Dr. Wang graduated from PekingUniversity in 1996 with a Bachelor's degree in Pharmacy, then obtained a Master's degree in Biochemistry from the National Doping Control Center in 1999, and obtained a dual degree in Doctor of Pharmacy and Master of Statistics from the University of Florida in 2003.。 Dr. Wang joined the FDA in 2003 and worked there for 18 years, from reviewer, senior reviewer, team leader, deputy director of science, acting director, to director of the Quantitative Pharmacology Review Department in the Clinical Pharmacology Review Office, until leaving the FDA in September 2021. During this period, Dr. Wang was responsible for quantitative pharmacology reviews, research projects, and policy formulation in all disease areas, and played a key role in the decision-making for the approval of new drugs for several major diseases.。

<END>
*版权声明:本网站所转载的文章,均来自互联网,旨在传递更多信息。鉴于互联网的开放性和文章创作的复杂性,我们无法保证所转载的所有文章均已获得原作者的明确授权。如果您是原作者或拥有相关权益,请与我们联系,我们将立即删除未经授权的文章。本网站转载文章仅为方便读者查阅和了解相关信息,并不代表我们认同其观点和内容。读者应自行判断和鉴别转载文章的真实性、合法性和有效性。
AI+生命科学全产业链智能数据平台

收藏

发表评论
评论区(0
  • 暂无评论

    摩熵医药企业版
    50亿+条医药数据随时查
    7天免费试用
    摩熵数科开放平台
    原料药
    十五五战略规划
    专利数据服务
    添加收藏
      新建收藏夹
      取消
      确认